Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary. The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce . statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound- Derived Coronary Atheroma Burden – ASTEROID. Mar 13, Share via: AddThis.

Author: Dunris Kigagar
Country: Azerbaijan
Language: English (Spanish)
Genre: Career
Published (Last): 28 November 2016
Pages: 370
PDF File Size: 7.10 Mb
ePub File Size: 16.41 Mb
ISBN: 969-3-25292-650-6
Downloads: 1922
Price: Free* [*Free Regsitration Required]
Uploader: Najind

Subsequently, every 60th image was analyzed, representing cross-sections spaced exactly 1. Everolimus for the prevention of hrial rejection and vasculopathy in cardiac-transplant recipients. Between November and Octoberpatients had a baseline IVUS examination and received at astreoid 1 dose of study drug.

All measurements were performed at the end of the study, after both the baseline and follow-up IVUS examinations were available. A second imputation method assigned the 22 patients who discontinued the study because of ischemic events to a progression rate calculated from the median value for all patients completing the trial who showed progression.

Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitative arteriography: Sign in to save your search Sign in to your personal account. Dr Davignon has received research support and rosuvaatatin fees from AstraZeneca.

Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion. Nat Clin Pract Cardiovasc Med.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Create a free personal account to download free article PDFs, sign up for alerts, and more. The study sought to determine the effects of high-intensity lipid lowering on coronary disease progression. This change represents a median reduction of 6.

The second prespecified primary efficacy parameter was the nominal change end of treatment minus baseline in total atheroma volume TAV in the mm subsegment of the coronary artery with the largest plaque volume at baseline the most diseased segment.

Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAVthe most rigorous IVUS measure of disease progression and regression.


All honoraria, consulting fees, or other payments from any for-profit entity are paid directly to charity, so that neither income nor any tax deduction is received. Rosuvastatin is the most recently introduced statin and typically produces greater reductions in LDL-C and larger increases in HDL-C than previously available agents. Previous reports have established the accuracy and reproducibility of this method. The disposition of these patients is summarized in Figure 1.

Hospital de Bellvitge, Barcelona E. After he received a nonsteroidal anti-inflammatory agent, renal failure developed, the family declined dialysis, and the patient died 5 days later. During this pullback, images were obtained at 30 frames per second and recorded on super-VHS videotape. Selection of Study Patients.

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. Only regression, defined as a reduction in IVUS measures of atheroma burden with CIs not including zero, would yield a successful outcome.

As each baseline videotape was received, the images were digitized and the date imprinted on the videotape was removed from each image using digital processing.

Trials using IVUS have successfully investigated the effects of a variety of antiatherosclerotic therapies, including statins, 12161719 blood pressure—lowering drugs, 14 reduction of inflammatory markers, 19 administration of a high-density lipoprotein HDL mimetic, 11 and novel investigative therapies. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

The paired studies were then randomly resequenced using codes provided by an outside statistician. The bottom 2 panels illustrate the same cross-sections, but with roshvastatin superimposed.

If regression of disease is the desired outcome, then asteroir LDL-C is better. The 2 examination results asteroiv then resequenced using random assignments generated by an outside statistician.

Postmortem examination revealed a fracture of the T11 vertebral body with local muscle hemorrhage.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Purchase access Subscribe to JN Learning for one year. Atherosclerosis is generally viewed as a chronic, progressive disease characterized by continuous accumulation of atheromatous plaque within the arterial wall.


In parallel to clinical outcomes trials, imaging studies have examined the effects of antiatherosclerotic ttrial on the progression of atherosclerosis. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein qsteroid with tral versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. We compensated for the absence of placebo controls by blinding date information on IVUS studies and resequencing the wsteroid to eliminate observer bias in interpretation.

Further studies are needed to determine the effect of the observed changes on clinical outcome. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment.

Nissen, MD ; Stephen J. Nissen, Nicholls, Schoenhagen, Crowe, Tuzcu. There were no cases of rhabdomyolysis. Statistical analysis was performed by the sponsor and the contract research organization under contract with the sponsor. This procedure was designed to provide the longest possible vessel segment for analysis. We recognize the limitations of the current study.

However, exploratory analyses imputing less favorable IVUS outcomes for these patients did not alter the conclusions. Analysis of variance, with region as a factor, was used for analysis of the percentage of change in lipid values. Astfroid statin treatment in patients with acute coronary syndrome: Patients treated with any lipid-lowering medication within the previous 4 weeks required a 4-week washout period before enrollment to obtain accurate baseline lipid values.

Our website uses cookies to enhance your experience. To allow for 2 primary efficacy parameters, a Bonferroni correction was prespecified and a significance level of. Two primary efficacy asteeoid were prespecified: There was no significant heterogeneity in the response to treatment for either of the 2 primary efficacy parameters for subgroups defined by age, sex, body mass index, history of diabetes mellitus, LDL-C levels, or HDL-C levels.

Moreover, arteries undergoing mechanical interventions were included, which could have affected atheroma measurements. Initial trials used quantitative coronary angiography or carotid ultrasound to determine the progression rates.